1. Home
  2. MXCT

as 12-11-2024 4:00pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Nasdaq

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

Founded: 1999 Country:
United States
United States
Employees: N/A City: ROCKVILLE
Market Cap: 375.0M IPO Year: 2021
Target Price: $9.50 AVG Volume (30 days): 753.4K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.34 EPS Growth: N/A
52 Week Low/High: $3.17 - $5.55 Next Earning Date: 11-06-2024
Revenue: $45,599,000 Revenue Growth: 19.85%
Revenue Growth (this year): -7.17% Revenue Growth (next year): 21.24%

MXCT Daily Stock ML Predictions

Stock Insider Trading Activity of MaxCyte Inc. (MXCT)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Erck Stanley C MXCT Director Nov 1 '24 Sell $3.72 47,689 $177,403.08 269,118
Johnston John Joseph MXCT Director Oct 28 '24 Sell $3.72 3,000 $11,166.00 141,950
Erck Stanley C MXCT Director Oct 1 '24 Sell $3.75 47,689 $178,751.93 269,118
Johnston John Joseph MXCT Director Sep 26 '24 Sell $3.82 3,000 $11,460.00 141,950

Share on Social Networks: